These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25300286)

  • 21. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes.
    Linn T; Fischer B; Soydan N; Eckhard M; Ehl J; Kunz C; Bretzel RG
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3839-46. PubMed ID: 18611975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes.
    Hershon KS; Blevins TC; Mayo CA; Rosskamp R
    Endocr Pract; 2004; 10(1):10-7. PubMed ID: 15251616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized clinical trial of the efficacy and safety of insulin glargine vs. NPH insulin as basal insulin for the treatment of glucocorticoid induced hyperglycemia using continuous glucose monitoring in hospitalized patients with type 2 diabetes and respiratory disease.
    Ruiz de Adana MS; Colomo N; Maldonado-Araque C; Fontalba MI; Linares F; García-Torres F; Fernández R; Bautista C; Olveira G; de la Cruz JL; Rojo-Martínez G; Valdés S
    Diabetes Res Clin Pract; 2015 Nov; 110(2):158-65. PubMed ID: 26474657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.
    Eliaschewitz FG; Calvo C; Valbuena H; Ruiz M; Aschner P; Villena J; Ramirez LA; Jimenez J;
    Arch Med Res; 2006 May; 37(4):495-501. PubMed ID: 16715577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin.
    Fiesselmann A; Wiesner T; Fleischmann H; Bramlage P
    Acta Diabetol; 2016 Oct; 53(5):717-26. PubMed ID: 27093968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.
    Bowering K; Reed VA; Felicio JS; Landry J; Ji L; Oliveira J
    Diabet Med; 2012 Sep; 29(9):e263-72. PubMed ID: 22672081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BASAL-BOLUS REGIMEN WITH INSULIN ANALOGUES VERSUS HUMAN INSULIN IN MEDICAL PATIENTS WITH TYPE 2 DIABETES: A RANDOMIZED CONTROLLED TRIAL IN LATIN AMERICA.
    Bueno E; Benitez A; Rufinelli JV; Figueredo R; Alsina S; Ojeda A; Samudio S; Cáceres M; Argüello R; Romero F; Echagüe G; Pasquel F; Umpierrez GE
    Endocr Pract; 2015 Jul; 21(7):807-13. PubMed ID: 26121460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patients.
    Dhital SM; Shenker Y; Meredith M; Davis DB
    Endocr Pract; 2012; 18(5):712-9. PubMed ID: 22784834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in inpatient glycemic control and response to subcutaneous insulin therapy between medicine and surgery patients with type 2 diabetes.
    Smiley D; Umpierrez GE; Hermayer K; Newton C; Jacobs S; Olson DE; Khan A; Rizzo M; Peng L; Reyes D; Cardona S; Fonseca V
    J Diabetes Complications; 2013; 27(6):637-41. PubMed ID: 23911535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of intensive glycaemic control on endothelial progenitor cells in patients with long-standing uncontrolled type 2 diabetes.
    Lev EI; Singer J; Leshem-Lev D; Rigler M; Dadush O; Vaduganathan M; Battler A; Kornowski R
    Eur J Prev Cardiol; 2014 Sep; 21(9):1153-62. PubMed ID: 23598596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alogliptin and Gliclazide Similarly Increase Circulating Endothelial Progenitor Cells in Type 2 Diabetes Patients.
    Negro R; Greco EL; Greco G
    Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):215-219. PubMed ID: 29558784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repetitive spikes of glucose and lipid induce senescence-like phenotypes of bone marrow stem cells through H3K27me3 demethylase-mediated epigenetic regulation.
    Horitani K; Iwasaki M; Kishimoto H; Wada K; Nakano M; Park H; Adachi Y; Motooka D; Okuzaki D; Shiojima I
    Am J Physiol Heart Circ Physiol; 2021 Nov; 321(5):H920-H932. PubMed ID: 34533398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of insulin glargine during pregnancy: A review.
    Jethwani P; Saboo B; Jethwani L; Chawla R; Maheshwari A; Agarwal S; Jaggi S
    Diabetes Metab Syndr; 2021; 15(1):379-384. PubMed ID: 33540243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple therapeutic effect of endothelial progenitor cell regulated by drugs in diabetes and diabetes related disorder.
    Ambasta RK; Kohli H; Kumar P
    J Transl Med; 2017 Aug; 15(1):185. PubMed ID: 28859673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An association of serum vistafin level and number of circulating endothelial progenitor cells in type 2 diabetes mellitus patients.
    Berezin AE; Samura TA; Kremzer AA; Berezina TA; Martovitskaya YV; Gromenko EA
    Diabetes Metab Syndr; 2016; 10(4):205-212. PubMed ID: 27377688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alterations in the Levels of Circulating and Endothelial Progenitor Cells Levels in Young Adults with Type 1 Diabetes: A 2-Year Follow-Up from the Observational METRO Study.
    Longo M; Scappaticcio L; Bellastella G; Pernice V; Cirillo P; Maio A; Castaldo F; Giugliano D; Esposito K; Maiorino MI;
    Diabetes Metab Syndr Obes; 2020; 13():777-784. PubMed ID: 32256094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response to Zanders et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care 2014;37:1360-1366.
    Bordeleau L; Gerstein HC
    Diabetes Care; 2014 Oct; 37(10):e223. PubMed ID: 25249683
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of glycemic variability on the levels of endothelial progenitor cells in patients with type 1 diabetes.
    Inaba Y; Tsutsumi C; Haseda F; Fujisawa R; Mitsui S; Sano H; Terasaki J; Hanafusa T; Imagawa A
    Diabetol Int; 2018 May; 9(2):113-120. PubMed ID: 30603358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycaemic Control Achieves Sustained Increases of Circulating Endothelial Progenitor Cells in Patients Hospitalized for Decompensated Diabetes: An Observational Study.
    Bonora BM; Cappellari R; Grasso M; Mazzucato M; D'Anna M; Avogaro A; Fadini GP
    Diabetes Ther; 2022 Jul; 13(7):1327-1337. PubMed ID: 35676613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.